IN-Licensing

Our profile and our experience in the Spanish market position us as an attractive
licensee for the successful marketing of new products.

Why us?

  • We are in one of the leading positions in the Spanish pharmaceutical company ranking
  • We are 100% R&D-oriented
  • We have an extensive track record in the marketing of ethical and hospital products
  • Our product portfolio comprises exclusively innovative products
  • We have a direct presence in Span and Portugal (more than 250 representatives)
  • Extensive experience in launching both our own and other companies’ new products
  • Our sales network is specialized
  • We have an excellent image in medical and pharmaceutical circles
  • And, finally, because we are veterans in relations with the health authorities in respect of national regulatory phases, pricing and product reimbursement.

What are we seeking?

We concentrate our activity principally on seven therapeutic areas:

  • Cardiovascular
  • Osteoarticular
  • Respiratory
  • Urology
  • Anesthesia/Pain relief
  • Central nervous system
  • Endocrinology
  • Primary healthcare
  • Diagnostic imaging contrast agents
  • We also have an OTC line

Strategic Alliances

As a group, we have a lengthy track record in strategic agreements, backed by our experience and our co-operation with both biotechnological and pharmaceutical companies and public research centres.

Our Agreements

OUT Licensing

We are working to grant licenses to other companies, with main purpose of maximizing the commercial potential of our internal R&D. At present, we have three licenses on offer for our products Bemiparin, Fibrilín®, Condroitín, Enoxaparin and Sodium Heparin.

Bemiparin

Our international molecule.

One of our success stories is the internationalization of bemiparin (low-molecular-weight heparin). As a result of the agreements reached with licensee companies, this heparin is present in 52 countries outside Spain.

Would you like to know more?
For more information on bemiparin, see www.bemiparin.com

Enoxaparin

Our biosimilar with a high growth potential.

ROVI’s history has been linked to heparins since we began, so this enoxaparin biosimilar is a logical evolution of our activity.

Would you like to know more?
Click for more information on Enoxaparin

Condroitín

Sulphate 400mg ROVI

Chondroprotector indicated for knee arthrosis.

We are also working to find new partners, so that this license can reach more people.

Fibrilín®

Our Class III health product with EC marking

We are working actively to internationalize Fibrilín®, our Class III health product with CE marking, for hospital use in locking catheters.

Would you like to know more?
For more information on Fibrilín®, see www.fibrilin.com